Clinical trials
catalyst calendar across sponsors →Studies where CRDF is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 expanded access · 3 with posted results
Held by 10 tracked-famous managers (JANE STREET GROUP, LLC, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, +5 more) · FINRA short interest 9.3 days to cover (settled 2026-07-31) · insider 90d: 2 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308Objective Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX | Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation | 110 | Nov 2026 | ≤ 103 d | 2026-06-16 |
| Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNCT04752696Overall Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Onvansertib, Nanoliposomal irinotecan, Leucovorin, Fluorouracil | Pancreatic Ductal Adenocarcinoma | 41 | 2024-12-24actual | — | 2025-12-22 |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationNCT05593328Overall Response RateRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Onvansertib, FOLFIRI, Bevacizumab | Colorectal Cancer, Metastatic Colorectal Cancer | 23 | 2024-12-09actual | — | 2025-01-10 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationNCT03829410results2025-03-04Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Onvansertib, FOLFIRI · Biological: Bevacizumab | Metastatic Colorectal Cancer, KRAS Gene Mutation | 68 | 2024-01-29actual | — | 2025-03-04 |
| Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034results2024-11-07Percentage of Participants Achieving Disease Control at or Before 12 WeeksNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Onvansertib, Abiraterone, Prednisone | Metastatic Castration-Resistant Prostate Cancer | 72 | 2023-10-16actual | — | 2024-11-07 |
| Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)NCT03303339results2023-02-27Number of Participants Who Experienced Dose Limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Onvansertib, Cytarabine, Decitabine | Acute Myeloid Leukemia | 72 | 2021-11-17actual | — | 2023-02-27 |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal CancerNCT04446793expanded access | — | No longer available | Drug: Onvansertib, FOLFIRI · Biological: Bevacizumab | Metastatic Colorectal Cancer, KRAS Gene Mutation | — | — | — | 2024-02-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19